^
    Back
    Association details:
    Biomarker:RBM6 deletion
    Cancer:Solid Tumor
    Drug:cisplatin (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Nucleic Acids Res
    Title:

    RBM6 splicing factor promotes homologous recombination repair of double-strand breaks and modulates sensitivity to chemotherapeutic drugs

    Published date:
    10/28/2021
    Excerpt:
    RBM6-deficient cancer cells are vulnerable to ATM and PARP inhibition and show remarkable sensitivity to cisplatin. Concordantly, cisplatin administration inhibits the growth of breast tumor devoid of RBM6 in mouse xenograft model.
    DOI:
    10.1093/nar/gkab976